MA32688B1 - Composes n-sulfonamido pyrazolyles polycycliques - Google Patents

Composes n-sulfonamido pyrazolyles polycycliques

Info

Publication number
MA32688B1
MA32688B1 MA33737A MA33737A MA32688B1 MA 32688 B1 MA32688 B1 MA 32688B1 MA 33737 A MA33737 A MA 33737A MA 33737 A MA33737 A MA 33737A MA 32688 B1 MA32688 B1 MA 32688B1
Authority
MA
Morocco
Prior art keywords
compounds
sulfonamido
polycyclic
cycle
pyrazolyl compounds
Prior art date
Application number
MA33737A
Other languages
Arabic (ar)
English (en)
Inventor
Andrei W Konradi
Xiaocong Michael Ye
Simeon Bowers
Albert W Garofalo
Danielle L Aubele
Darren Dressen
Raymond Ng
Gary Probst
Christopher M Semko
Minghua Sun
Anh P Truong
Michael S Dappen
Original Assignee
Elan Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc filed Critical Elan Pharm Inc
Publication of MA32688B1 publication Critical patent/MA32688B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE DES COMPOSÉS POSSÉDANT UNE STRUCTURE SELON LES FORMULES (1), (2), (3), ET (4), AVEC LE CYCLE A, LE CYCLE B, LE CYCLE C, M, N, R25, R50, ET R51 ÉTANT TELS QUE DÉFINIS DANS LA DESCRIPTION. L'INVENTION CONCERNE ÉGALEMENT DES COMPOSITIONS PHARMACEUTIQUES COMPRENANT DES COMPOSÉS DE FORMULES (1), (2), (3), ET (4), AINSI QUE DES PROCÉDÉS DE TRAITEMENT DE TROUBLES COGNITIFS, TELS QUE LA MALADIE D'ALZHEIMER. L'INVENTION PORTE EN OUTRE SUR DES PRODUITS SEMI-OUVRÉS UTILES DANS LA PRÉPARATION DES COMPOSÉS DE FORMULE (1), (2), (3), ET (4).
MA33737A 2008-09-05 2011-04-01 Composes n-sulfonamido pyrazolyles polycycliques MA32688B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9479908P 2008-09-05 2008-09-05
US9924108P 2008-09-23 2008-09-23
US17327809P 2009-04-28 2009-04-28
US22653209P 2009-07-17 2009-07-17
PCT/US2009/055987 WO2010028213A2 (fr) 2008-09-05 2009-09-04 Composés n-sulfonamido pyrazolyles polycycliques

Publications (1)

Publication Number Publication Date
MA32688B1 true MA32688B1 (fr) 2011-10-02

Family

ID=41258775

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33737A MA32688B1 (fr) 2008-09-05 2011-04-01 Composes n-sulfonamido pyrazolyles polycycliques

Country Status (20)

Country Link
US (1) US8283358B2 (fr)
EP (1) EP2346863A2 (fr)
JP (1) JP2012502051A (fr)
KR (1) KR20110055715A (fr)
CN (1) CN102203089A (fr)
AR (1) AR073497A1 (fr)
AU (1) AU2009289579A1 (fr)
BR (1) BRPI0918213A2 (fr)
CA (1) CA2736767A1 (fr)
CL (1) CL2011000405A1 (fr)
CO (1) CO6362008A2 (fr)
EA (1) EA201170421A1 (fr)
EC (1) ECSP11010947A (fr)
IL (1) IL211263A0 (fr)
MA (1) MA32688B1 (fr)
MX (1) MX2011002047A (fr)
PE (1) PE20110418A1 (fr)
TW (1) TW201014856A (fr)
WO (1) WO2010028213A2 (fr)
ZA (1) ZA201101994B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009289649B2 (en) 2008-09-03 2016-05-05 Biomarin Pharmaceutical Inc. Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors
AR073497A1 (es) 2008-09-05 2010-11-10 Elan Pharm Inc Compuestos de pirazolilo policiclicos de n-sulfonamido
WO2012118782A1 (fr) 2011-02-28 2012-09-07 Repligen Corporation Inhibiteurs de l'histone déacétylase
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US10029988B2 (en) 2013-03-15 2018-07-24 Biomarin Pharmaceutical Inc. HDAC inhibitors
CN114929235A (zh) * 2020-01-03 2022-08-19 布鲁奥科制药有限公司 用于治疗cns病症的化合物和组合物
CN111909217B (zh) * 2020-08-20 2023-05-02 昆明贵金属研究所 一种双（二叔丁基-4-二甲氨基苯基膦）四溴双钯(ⅱ)化合物及其制备方法和用途
CN115448892B (zh) * 2022-09-19 2023-07-07 郑州铁路职业技术学院 一种苯并噻二唑杂环化合物的合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8727989D0 (en) * 1987-11-30 1988-01-06 Merck Sharp & Dohme Therapeutic agents
EP0330788A1 (fr) 1988-03-01 1989-09-06 Merrell Dow Pharmaceuticals Inc. Utilisation des dérivés de la quinolizine et de la quinolizinone pour la manufacture des médicaments pour le traitement de l'arythmie cardiaque
EP1758884A2 (fr) * 2004-05-20 2007-03-07 Elan Pharmaceuticals, Inc. Inhibiteurs sulfonamido n-cycliques de gamma-secretase
AU2006283567A1 (en) * 2005-08-19 2007-03-01 Elan Pharmaceuticals, Inc. Bridged N-bicyclic sulfonamido inhibitors of gamma secretase
UY30377A1 (es) * 2006-06-02 2008-01-02 Elan Pharm Inc Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
CN101128035B (zh) 2006-08-18 2011-08-24 中兴通讯股份有限公司 时分码分多址系统中信道间的定时方法
WO2008147800A1 (fr) * 2007-05-25 2008-12-04 Elan Pharmaceuticals, Inc. Pyrazolopyrrolidines en tant qu'inhibiteurs de gamma sécrétase
AR073497A1 (es) 2008-09-05 2010-11-10 Elan Pharm Inc Compuestos de pirazolilo policiclicos de n-sulfonamido

Also Published As

Publication number Publication date
US20100081680A1 (en) 2010-04-01
IL211263A0 (en) 2011-04-28
WO2010028213A2 (fr) 2010-03-11
EP2346863A2 (fr) 2011-07-27
MX2011002047A (es) 2011-06-17
BRPI0918213A2 (pt) 2015-12-08
CL2011000405A1 (es) 2011-07-01
CO6362008A2 (es) 2012-01-20
ZA201101994B (en) 2011-11-30
WO2010028213A3 (fr) 2010-06-03
CA2736767A1 (fr) 2010-03-11
EA201170421A1 (ru) 2012-01-30
TW201014856A (en) 2010-04-16
AR073497A1 (es) 2010-11-10
ECSP11010947A (es) 2011-07-29
KR20110055715A (ko) 2011-05-25
US8283358B2 (en) 2012-10-09
JP2012502051A (ja) 2012-01-26
AU2009289579A1 (en) 2010-03-11
CN102203089A (zh) 2011-09-28
PE20110418A1 (es) 2011-06-22

Similar Documents

Publication Publication Date Title
MA32688B1 (fr) Composes n-sulfonamido pyrazolyles polycycliques
MA47447B1 (fr) 2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides pour le traitement du cancer
MA38146A1 (fr) Nouveaux dérivés du benzimidazole comme antagonistes ep4
MA29411B1 (fr) 1h-quinazoline -2,4-diones et leur utilisation en tant que ligands du recepteur ampa
MA34308B1 (fr) Triazolopyridines substituées
MA33450B1 (fr) Dérivés d&#39;oxazine et leur utilisation en tant qu&#39;inhibiteurs de bace pour le traitement de troubles neurologiques
MA37798B1 (fr) 4-méthyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphtalènes
MA35422B1 (fr) Imidazopyridazines amino-substituees
MA52492B1 (fr) Composés inhibiteurs de rip1, procédés de préparation et d&#39;utilisation associés
MA38090B1 (fr) Dérivés de 5-fluoro-n-(pyridin -2-yl)pyridin-2-amines contenant un groupe sulfoximine
MA32104B1 (fr) Dérivés d&#39;oxime en tant qu&#39;inhibiteurs de hsp90
MA33726B1 (fr) Composes de dioxyde d&#39;iminothiadiazine comme inhibiteurs de bace, compositions et leur utlisation
MA31952B1 (fr) Pyrrolopyrimidines et pyrrolopyridines
MA30694B1 (fr) Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique.
MA34019B1 (fr) Aryltriazolone liée à un bis-aryle et son utilisation
MA34898B1 (fr) Nouveaux dérivés hétérocycliques et leur utilisation dans le traitement de troubles neurologiques
MA29170B1 (fr) Derives puriniques agissant comme des agonistes du recepteur a2a
MA30406B1 (fr) Nouveaux composes
MA29615B1 (fr) Preparations et methodes pour le diagnostic et le traitement d&#39;une tumeur
MA33299B1 (fr) Nouvelle formulation de naproxène
MA29723B1 (fr) Composes
MA32798B1 (fr) Acides naphtylacétiques
MA33419B1 (fr) Composés et compositions pour le traitement de maladies parasitaires
MA31832B1 (fr) Dérivés de quinazolinedione, leur préparation et leurs applications thérapeutiques
MA35444B1 (fr) Ligands du récepteur ep1